Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2642-2647

  Fenton, Robert J ^a   Morley, Peter J ^a   Owens, Ian J ^a   Gower, David ^a   Parry, Simon ^a   Crossman, Lee ^a   Wong, Tony ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG CLEARANCE; DRUG POTENCY; DRUG RETENTION; FERRET; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; LUNG CLEARANCE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; WHOLE BODY AUTORADIOGRAPHY;

EID: 0032729627     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2642     Document Type: Article

References (33)

1. Arden, N. H., P. A. Patriarch, M. B. Fasano, K. J. Lui, M. W. Harmon, A. P. Kendal, and D. Rimland. 1988. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza (H3N2) in a nursing home. Arch. Intern. Med. 148:865-868.
2. Belshe, R. B., M. H. Smith, C. B. Hall, R. Betts, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1508-1512.
3. Betts, R. F., J. J. Treanor, P. S. Graman, D. W. Bentley, and R. Dolin. 1987. Antiviral agents to prevent or treat influenza in the elderly. J. Respir. Dis. 8(Suppl. 11A):S56-S59.
4. Carrat, F., A. Tachet, C. Rouzioux, B. Housset, and A. J. Valleron. 1998. Influenza vaccine and morbidity. Field investigation of influenza vaccine effectiveness on morbidity. Vaccine 16:893-898.
5. Cass, L. M. R., C. Efthymiopoulos, and A. Bye. 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36(Suppl. 1):1-11.
6. Claas, E. C. J., A. D. M. E. Osterhaus, R. Vanbeek, J. C. Dejong, G. F. Rimmelzwaan, D. A. Senne, S. Krauss, K. F. Shortridge, and R. G. Webster. 1998. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351:472-477.
7. Dolin, R., R. C. Reichman, H. P. Madore, R. Maynard, P. N. Linton, and J. Webber-Jones. 1982. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl. J. Med. 307:580-584.
8. Douglas, R. G., Jr. 1990. Prophylaxis and treatment of influenza. N. Engl. J. Med. 322:443-450.
9. Efthymiopoulos, C., P. Barrington, J. Patel, A. Harker, A. Harris, E. K. Hussey, and A. Bye. 1994. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal and inhaled administration in man, abstr. H70, p. 265. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Gubareva, L. V., J. A. McCullers, R. C. Bethell, and R. G. Webster. 1998. Characterisation of influenza A/Hong Kong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J. Infect. Dis. 178:1592-1596.
11. Hayden, F. G., H. E. Hoffman, and D. A. Spyker. 1983. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob. Agents Chemother. 23:458-464.
12. Hayden, F. G., J. J. Treanor, R. F. Betts, M. Lobo, J. D. Esinhart, and E. K. Hussey. 1996. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 275:295-299.
13. Hayden, F. G., A. D. M. E. Osterhaus, J. J. Treanor, D. M. Fleming, F. Y. Aoki, K. G. Nicholson, A. M. Bohnen, H. M. Hirst, O. Keene, and K. Wightman. 1997. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337:874-880.
14. Monto, A. S., and N. H. Arden. 1992. Implications of viral resistance to amantadine in control of influenza A. Clin. Infect. Dis. 15:362-369.
15. Monto, A. S., D. P. Robinson, M. L. Herlocher, J. M. Hinson, M. J. Elliott, and A. Crisp. 1999. Zanamivir in the prevention of influenza among healthy adults. JAMA 282:31-35.
16. Oates, J. A., and A. J. J. Wood. 1990. Prophylaxis and treatment of influenza. N. Engl. J. Med. 322:443-450.
17. Palache, A. M. 1997. Influenza vaccines - a reappraisal of their use. Drugs 54:841-856.
18. Peng, G., R. Jennings, C. W. Potter, and J. S. Oxford. 1986. Amantadine resistance in clinical influenza (H3N2 and H1N1) virus isolates. J. Antimicrob. Chemother. 18(Suppl. B):135-140.
19. Potter, C. W., J. S. Oxford, S. L. Shore, C. McLaren, and C. H. Stuart-Harris. 1972. Immunity to influenza in ferrets. I. Response to live and killed virus. Br. J. Exp. Pathol. 53:153-167.
20. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent end points. Am. J. Hyg. 27:493-497.
21. Reuman, P. D., D. I. Bernstein, M. C. Keefer, E. C. Young, J. R. Sherwood, and G. M. Schif. 1989. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 11:27-40.
22. Ryan, D. M., J. Ticehurst, M. H. Dempsey, and C. R. Penn. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydn-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
23. Ryan, D. M., J. Ticehurst, and M. H. Dempsey. 1995. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob. Agents Chemother. 39:2583-2584.
24. Schilling, M., L. Povinelli, P. Krause, M. Gravenstein, A. Ambrozaitis, H. H. Jones, P. Drinka, P. Shult, D. Powers, and S. Gravenstein. 1998. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 16:1771-1774.
25. Sears, S. D., and M. L. Clements. 1987. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob. Agents Chemother. 31:1470-1473.
26. Sidwell, R. W., J. H. Huffman, D. L. Barnard, K. W. Bailey, M.-H. Wong, A. Morrison, T. Syndergaard, and C. U. Kim. 1998. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuramnidase inhibitor. Antivir. Res. 37:107-120.
27. Silagy, C., K. Campion, S. Gardiner, and M. Gummer. 1998. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352:1877-1881.
28. Smorodintsev, A. A., D. M. Zlydnikov, A. M. Kiseleva, J. A. Romanov, A. P. Kazantsev, and V. I. Rumovsky. 1970. Evaluation of amantadine in artificially induced A2 and B influenza. JAMA 213:1448-1454.
29. Tominack, R. L., and F. G. Hayden. 1985. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect. Dis. Clin. North Am. 1:459-478.
30. von Itzstein, M., W.-Y. Wu, G. B. Kok, M. S. Pegg, J. C. Dyason, B. Jin, T. V. Phan, M. L. Smythe, H. F. White, S. W. Oliver, P. M. Colman, J. N. Varghese, D. M. Ryan, J. M. Woods, R. C. Bethell, V. J. Hotham, J. M. Cameron, and C. R. Penn. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (London) 363:418-423.
31. Weixing, L. I., P. A. Escarpe, E. J. Eisenberg, K. C. Cundy, C. Sweet, K. J. Jakeman, J. Merson, W. Lew, L. Zhang, C. U. Kim. N. Bischofberger, M. S. Chen, and D. B. Mendel. 1998. Identification of GS4104 as an orally bio-available prodrug of the influenza virus neuraminidase inhibitor GS4071. Antimicrob. Agents Chemother. 42:647-653.
32. Wilson, S. Z., V. Knight, P. R. Wyde, S. Drake, and R. B. Couch. 1980. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob. Agents Chemother. 17:642-648.
33. Woods, J. M., R. C. Bethell, J. A. V. Coates, N. Healey, S. A. Hiscox, B. A. Pearson, D. M. Ryan, J. Ticehurst, J. Tilling, S. A. Walcott, and C. R. Penn. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.